Should I Buy TOVX? TOVX 2026 Analysis

Should You Buy Theriva Biologics Inc (TOVX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

0.190

1 Day change

-2.62%

52 Week Range

1.750

Analysis Updated At

2026/01/26

Theriva Biologics Inc (TOVX) is not a good buy for a beginner investor with a long-term strategy at this time. The technical indicators are bearish, financial performance is weak, and there are no positive catalysts or trading signals to support a buy decision. The stock lacks significant momentum or growth prospects to justify investment.

Technical Analysis

The technical indicators for TOVX are bearish. The MACD is below 0 and negatively contracting, the RSI is neutral at 44.741, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 0.202, with resistance at 0.218 and support at 0.185.

Options Data

Positive Catalysts

NULL. There are no recent news, significant insider or hedge fund activity, or trading signals to indicate a positive catalyst.

Neutral/Negative Catalysts

Additionally, the stock trend analysis shows limited upside potential, with only a 37.77% chance of a 0.53% increase in the next week.

Financial Performance

In Q3 2025, the company reported no revenue growth (0% YoY), a net income drop of -43.55% YoY to -$4,361,000, and a significant EPS decline of -93.39% YoY to -0.45. Gross margin remained at 0%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target changes are available for TOVX.

Analyst Rating

Wall Street analysts forecast TOVX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TOVX is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold

Sell

Current: 0.191

Low

Averages

High

Current: 0.191

Low

Averages

High

Maxim

Buy

Hold

downgrade

AI Analysis

2025-05-08

Reason

Maxim

Price Target

AI Analysis

2025-05-08

downgrade

Buy

Hold

Reason

Maxim downgraded Theriva Biologics to Hold from Buy.

Maxim

Buy

Hold

downgrade

2025-05-08

Reason

Maxim

Price Target

2025-05-08

downgrade

Buy

Hold

Reason

Maxim downgraded Theriva Biologics to Hold from Buy with no price target. The firm cites the company having announced top-line data from the Phase 2b VIRAGE study evaluating oncolytic virus candidate VCN-01 in combination with chemotherapy vs. chemotherapy alone in 1st line pancreatic cancer, noting that while the key measure of median overall survival demonstrated a 2.2 month improvement and a p value of 0.0546 was just over the threshold for statistical significance, in pancreatic cancer, the mOS is key and came in narrower than expected based on the prior data. Maxim calls the overall data "mixed and unimpressive".

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TOVX

Unlock Now

TOVX Should I Buy

TOVX Should I Buy

Should You Buy Theriva Biologics Inc (TOVX) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch